Hypofibrinogenemia is an independent predictor of hemophagocytic lymphohistiocytosis in children with sepsis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 10 2023
20 10 2023
Historique:
received:
26
10
2022
accepted:
10
10
2023
medline:
1
11
2023
pubmed:
21
10
2023
entrez:
20
10
2023
Statut:
epublish
Résumé
Hemophagocytic lymphohistiocytosis (HLH) is a potentially life-threatening condition in children with sepsis. We herein aimed to identify clinical and laboratory predictors of HLH in children with sepsis. We conducted a retrospective study of 568 children with sepsis admitted to Guangdong Women and Children Hospital from January 2019 to June 2022. HLH, while rare (6.34%), proved to be a highly fatal complication (37.14%) in children with sepsis. Children with HLH had higher levels of aspartate aminotransferase, lactate dehydrogenase, triglycerides, and ferritin than children without HLH; conversely, they displayed decreased levels of neutrophils, hemoglobin, platelets, fibrinogen, and albumin. Additionally, the HLH group showed higher rates of prolonged fever (> 10 days), hepatomegaly, and splenomegaly than the non-HLH group. Our retrospective analysis identified hypofibrinogenemia (OR = 0.440, P = 0.024) as an independent predictor for the development of HLH in patients with sepsis. The optimal cutoff value for fibrinogen was found to be < 2.43 g/L. The area under the curve for diagnosing HLH was 0.80 (95% confidence interval: 0.73-0.87, P < 0.0001), with a sensitivity of 72.41% and specificity of 76.27%. Thus, hypofibrinogenemia emerges as a potentially valuable predictor for HLH in children with sepsis.
Identifiants
pubmed: 37863910
doi: 10.1038/s41598-023-44628-z
pii: 10.1038/s41598-023-44628-z
pmc: PMC10589207
doi:
Substances chimiques
Fibrinogen
9001-32-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17936Informations de copyright
© 2023. Springer Nature Limited.
Références
Pediatr Blood Cancer. 2017 Apr;64(4):
pubmed: 27781387
World J Crit Care Med. 2018 Nov 30;7(6):73-83
pubmed: 30596029
J Pediatr Hematol Oncol. 2017 Aug;39(6):e303-e306
pubmed: 28697170
Pediatr Blood Cancer. 2007 Feb;48(2):124-31
pubmed: 16937360
Am J Med. 2014 Nov;127(11):1118-1125
pubmed: 24835040
Br J Haematol. 2016 Jul;174(2):175-87
pubmed: 27292929
Crit Care Med. 2020 Apr;48(4):459-465
pubmed: 32205591
Yonsei Med J. 2014 May;55(3):753-9
pubmed: 24719144
Annu Rev Med. 2012;63:233-46
pubmed: 22248322
Arthritis Rheumatol. 2014 Sep;66(9):2613-20
pubmed: 24782338
J Cancer Res Clin Oncol. 2020 Apr;146(4):1065-1077
pubmed: 32076823
Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):e373-e380
pubmed: 30037588
Pediatr Crit Care Med. 2018 May;19(5):491-492
pubmed: 29727417
Turk J Med Sci. 2019 Oct 24;49(5):1332-1335
pubmed: 31648438
Braz J Med Biol Res. 2019;52(4):e8595
pubmed: 30994733
Crit Rev Oncol Hematol. 2017 Jun;114:1-12
pubmed: 28477737
Best Pract Res Clin Rheumatol. 2020 Aug;34(4):101515
pubmed: 32387063
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Eur Ann Allergy Clin Immunol. 2017 Jan;49(1):31-41
pubmed: 28120605
Blood. 2010 Dec 23;116(26):5824-31
pubmed: 20855862
Arch Pathol Lab Med. 2001 Jul;125(7):888-91
pubmed: 11419972
Eur J Pediatr. 2007 Feb;166(2):95-109
pubmed: 17151879
Pediatr Crit Care Med. 2018 May;19(5):397-405
pubmed: 29470247
Indian J Crit Care Med. 2012 Oct;16(4):198-203
pubmed: 23559726
PLoS One. 2015 Mar 30;10(3):e0121919
pubmed: 25822614
Swiss Med Wkly. 2018 Sep 23;148:w14641
pubmed: 30378643
Intensive Care Med. 2010 Oct;36(10):1695-1702
pubmed: 20532477
Curr Opin Immunol. 2017 Dec;49:20-26
pubmed: 28866302